Royce & Associates’s Axogen AXGN Stock Holding History

Royce & Associates’s Portfolio AXGN Stock Details AXGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.35M	Sell	72,516 -41,013	-36%	-$1.65M	0.03%	552
2026 Q1	$3.76M	Sell	113,529 -54,510	-32%	-$1.77M	0.04%	503
2025 Q4	$5.5M	Sell	168,039 -33,005	-16%	-$812K	0.06%	448
2025 Q3	$3.59M	Buy	+201,044	New	+$2.92M	0.04%	520
2019 Q1	–	Sell	-101,000	Closed	-$2.06M	–	1141
2018 Q4	$2.06M	Buy	101,000 +41,000	+68%	+$1.28M	0.02%	722
2018 Q3	$2.21M	Hold	60,000	–	–	0.02%	805
2018 Q2	$3.02M	Sell	60,000 -8,000	-12%	-$353K	0.02%	737
2018 Q1	$2.48M	Buy	+68,000	New	+$2.09M	0.02%	794
2016 Q4	–	Sell	-20,000	Closed	-$181K	–	1084
2016 Q3	$181K	Buy	+20,000	New	+$163K	﹤0.01%	1045
2015 Q2	–	Sell	-8,000	Closed	-$28K	–	1214
2015 Q1	$28K	Sell	8,000 -4,000	-33%	-$13.7K	﹤0.01%	1215
2014 Q4	$43K	Hold	12,000	–	–	﹤0.01%	1269
2014 Q3	$29K	Hold	12,000	–	–	﹤0.01%	1371
2014 Q2	$33K	Hold	12,000	–	–	﹤0.01%	1398
2014 Q1	$37K	Hold	12,000	–	–	﹤0.01%	1386
2013 Q4	$54K	Hold	12,000	–	–	﹤0.01%	1387
2013 Q3	$53K	Buy	+12,000	New	+$44.1K	﹤0.01%	1399

Other funds holding AXGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Royce & Associates's AXGN Position: Q2 2026 in Review

Royce & Associates reduced its Axogen (AXGN) stake by 36% in Q2 2026, selling an estimated $1.65M and leaving 72,516 shares worth $3.35M. The position accounts for 0.03% of the portfolio, ranked #552.

Royce & Associates first reported a position in AXGN in Q3 2013 and has held it in 16 quarters since. The position peaked at $5.5M in Q4 2025. 253 funds tracked by Wall St. Rank hold AXGN as of Q2 2026.

Royce & Associates held 72,516 shares of Axogen worth $3.35M as of Q2 2026.
Royce & Associates sold 41,013 Axogen shares in Q2 2026, an estimated $1.65M.
Axogen made up 0.03% of Royce & Associates's portfolio in Q2 2026, its #552 holding.
Royce & Associates first reported a position in Axogen in Q3 2013 and has held it in 16 quarters since.
Royce & Associates's Axogen position peaked at $5.5M in Q4 2025.
253 funds tracked by Wall St. Rank held Axogen as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.